α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

BACKGROUND: Checkpoint blockade immunotherapy has improved metastatic cancer patient survival, but response rates remain low. There is an unmet need to identify mechanisms and tools to circumvent resistance. In human patients, responses to checkpoint blockade therapy correlate with tumor mutation lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., Del Rosario, R., Li, O., Buchmann, T., Liang, B., Malato, J., Arce Vargus, F., Sheppard, D., Hann, B. C., Mirza, A., Quezada, S. A., Rosenblum, M. D., Krummel, M. F., Balmain, A., Akhurst, R. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399967/
https://www.ncbi.nlm.nih.gov/pubmed/30832732
http://dx.doi.org/10.1186/s40425-018-0493-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399967/
https://www.ncbi.nlm.nih.gov/pubmed/30832732
http://dx.doi.org/10.1186/s40425-018-0493-9

Ejemplares similares